4th FY Khoo Memorial Lecture 2008 nasopharyngeal cancer workgroup - The past, the present and the future

Annals of the Academy of Medicine Singapore

Volumn 37, Issue 7, 2008, Pages 606-614

  Wee, Joseph ^a  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; MITOMYCIN C; PACLITAXEL; PLATINUM DERIVATIVE; VINCRISTINE;

ADJUVANT THERAPY; ADVANCED CANCER; ALLOGENEIC STEM CELL TRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER STAGING; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL RESEARCH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CONTINUOUS INFUSION; DIAGNOSTIC IMAGING; DISEASE FREE SURVIVAL; DRUG EFFICACY; HEAD AND NECK CANCER; HONG KONG; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MEDICAL SOCIETY; METASTASIS; MOUSE; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CANCER; NONHUMAN; PHASE 3 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RADIATION DOSE; RADIOLOGIST; SINGAPORE; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; ARTICLE; METHODOLOGY; MORTALITY; NASOPHARYNX TUMOR;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; HUMANS; NASOPHARYNGEAL NEOPLASMS; RADIOTHERAPY, INTENSITY-MODULATED; RESEARCH DESIGN; SINGAPORE;

EID: 49449113097     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (66)

1. Khoo FY, Chia KB, Nalpon J. A new technique of contrast examination of the nasopharynx with cinefluorography and roentgenography. Am J Roentgenol Radium Ther Nucl Med 1967;99:238-48.
2. Chong VFH, Tsao SY. Nasopharyngeal carcinoma. Armour Publishing, Singapore, 1997.
3. th ASTRO, Los Angeles, USA, 2007.
4. Heng DM, Wee J, Fong KW, Lian LG, Sethi VK, Chua ET, et al. Prognostic factors in 677 patients with non-disseminated nasopharyngeal carcinoma in Singapore. Cancer 1999;86:1912-20.
5. Lee AW, Poon YF, Foo W, Law SC, Cheung FK, Chan DK, et al. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: overall survival and patterns of failure. Int J Radiat Oncol Biol Phys 1992;23:261-70.
6. th International Conference on Head and Neck Cancer, Toronto, Canada 1996.
7. Tham WK, Yap SP, Tuan J, Hee SW, Wee J. Retropharyngeal nodal metastasis is related to a higher rate of distant metastasis in patients with nasopharyngeal cancer - results from a single centre retrospective study. Proceedings ECCO-14, Barcelona, Spain 2007. Eur J Cancer 2007;Suppl 5:331.
8. Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998;16:1310-7.
9. Chan AT, Teo PM, Johnson PJ. Controversies in the management of locoregionally advanced nasopharyngeal carcinoma. Curr Opin Oncol 1998;10:219-25.
10. Tan EH, Chua ET, Wee J, Tan T, Fong KW, Ang PT, et al. Concurrent chemoradiotherapy followed by adjuvant chemotherapy in Asian patients with nasopharyngeal cancer: toxicities and preliminary results. Int J Radiat Oncol Biol Phys 1999;45:597-601.
11. Wee J, Tan EH, Tai BC, Wong HB, Leong SS, Tan T, et al. Randomized trial of radiotherapy versus concurrent chemo-radiotherapy followed by adjuvant chemotherapy in patients with AJCC/UICC (1997) Stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol 2005;23:6730-8.
12. Lee AW, Lau WH, Tung SY, Chua DT, Chappell R, Xu L, et al; Hong Kong Nasopharyngeal Cancer Study Group. Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin Oncol 2005;23:6966-75.
13. Chan AT, Leung SF, Ngan RK, Teo PM, Lau WH, Kwan WH, et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst 2005;97:536-9.
14. Lin JC, Jan JS, Hsu CY, Liang WM, Jiang RS, Wang WY. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol 2003;21:631-7.
15. Zhang L, Zhao C, Peng PJ, Lu LX, Huang PY, Han F, et al. Phase III study comparing standard radiotherapy with or without weekly oxaliplatin in treatment of locoregionally advanced nasopharyngeal carcinoma: preliminary results. J Clin Oncol 2005;23:8461-8.
16. Kwong DL, Sham JS, Au GK, Chua DT, Kwong PW, Cheng AC, et al. Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study. J Clin Oncol 2004;22:2643-53.
17. Ma J, Chen Y, Liu MZ, Liang SB, Zong JF, Guo Y, et al. Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy versus radiotherapy alone in patients with locoregionally advanced Nasopharyngeal Carcinoma in endemic regions. Proceedings East West Symposium on Nasopharyngeal Carcinoma. Sunshine Coast, Australia, 2007.
18. Chan AT, Teo PM, Ngan RK, Leung TW, Lau WH, Zee B, et al. Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol 2002;20:2038-44.
19. Teo P, Tsao SY, Shiu W, Leung WT, Tsang V, Yu P, et al. A clinical study of 407 cases of nasopharyngeal carcinoma in Hong Kong. Int J Radiat Oncol Biol Phys 1989;17:515-30.
20. Lee AW, Sze WM, Au JS, Leung SF, Leung TW, Chua DT, et al. Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience. Int J Radiat Oncol Biol Phys 15;61:1107-16.
21. Lo YM. Prognostic implication of pretreatment plasma/serum concentration of Epstein-Barr virus DNA in nasopharyngeal carcinoma. Biomed Pharmacother 2001;55:362-5.
22. Leung SF, Chan AT, Zee B, Ma B, Chan LY, Johnson PJ, et al. Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type. Cancer 2003;98:288-91.
23. Lin JC, Wang WY, Chen KY, Wei YH, Liang WM, Jan JS, et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 2004;350:2461-70.
24. Chan KC, Chan AT, Leung SF, Pang JC, Wang AY, Tong JH, et al. Investigation into the origin and tumoral mass correlation of plasma Epstein-Barr virus DNA in nasopharyngeal carcinoma. Clin Chem 2005;51:2192-5.
25. Lee AW, Tung SY, Chan AT, Chappell R, Fu YT, Lu TX, et al. Preliminary results of a randomized study (NPC-9902 Trial) on therapeutic gain by concurrent chemotherapy and/or accelerated fractionation for locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2006;66:142-51.
26. Lin JC, Liang WM, Jan JS, Jiang RS, Lin AC. Another way to estimate outcome of advanced nasopharyngeal carcinoma - is concurrent chemoradiotherapy adequate? Int J Radiat Oncol Biol Phys 2004;60:156-64.
27. Chua DT, Ma J, Sham JS, Mai HQ, Choy DT, Hong MH, et al. Improvement of survival after addition of induction chemotherapy to radiotherapy in patients with early-stage nasopharyngeal carcinoma: Subgroup analysis of two Phase III trials. Int J Radiat Oncol Biol Phys 2006;65:1300-6.
28. Ma BB, King A, Lo YM, Yau YY, Zee B, Hui EP, et al. Relationship between pretreatment level of plasma Epstein-Barr virus DNA, tumor burden, and metabolic activity in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2006;66:714-20.
29. Rossi A, Molinari R, Boracchi P, Del Vecchio M, Marubini E, Nava M, et al. Adjuvant chemotherapy with vincristine, cyclophosphamide, and doxorubicin after radiotherapy in local-regional nasopharyngeal cancer: results of a 4-year multicenter randomized study. J Clin Oncol 1988;6:1401-10.
30. Chi KH, Chang YC, Guo WY, Leung MJ, Shiau CY, Chen SY, et al. A phase III study of adjuvant chemotherapy in advanced nasopharyngeal carcinoma patients. Int J Radiat Oncol Biol Phys 2002;52:1238-44.
31. Kwong DL, Sham JS, Au GK, Chua DT, Kwong PW, Cheng AC, et al. Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study. J Clin Oncol 2004;22:2643-53.
32. Hui EP, Ma BB, Leung SF, King A, Mo F, Kam MK, et al. Efficacy of neoadjuvant docetaxel and cisplatin followed by concurrent cisplatin- radiotherapy in locally advanced nasopharyngeal carcinoma (NPC): A randomized phase II study. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(June 20 Suppl):6037.
33. Bourhis J, Overgaard J, Audry H, Ang KK, Saunders M, Bernier J, et al; Meta-Analysis of Radiotherapy in Carcinomas of Head and neck (MARCH) Collaborative Group. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 2006;368:843-54.
34. Lee N, Xia P, Quivey JM, Sultanem K, Poon I, Akazawa C, et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys 2002;53:12-22.
35. Kam MK, Teo PM, Chau RM, Cheung KY, Choi PH, Kwan WH, et al. Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience. Int J Radiat Oncol Biol Phys 2004;60:1440-50.
36. Posner MR. Paradigm shift in the treatment of head and neck cancer: the role of neoadjuvant chemotherapy. Oncologist 2005;10 Suppl 3:11-9.
37. Pignon JP, le Maître A, Bourhis J; MACH-NC Collaborative Group. Meta-Analyses of Chemotherapy in Head and Neck Cancer (MACH-NC): an update. Int J Radiat Oncol Biol Phys 2007;69(2 Suppl):S112-4.
38. Monnerat C, Faivre S, Temam S, Bourhis J, Raymond E. End points for new agents in induction chemotherapy for locally advanced head and neck cancers. Ann Oncol 2002;13:995-1006.
39. Baujat B, Audry H, Bourhis J, Chan AT, Onat H, Chua DT, et al; MAC-NPC Collaborative Group. Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys 2006;64:47-56.
40. Brockstein B, Haraf DJ, Rademaker AW, Kies MS, Stenson KM, Rosen F, et al. Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. Ann Oncol 2004;15:1179-86.
41. Hong RL, Ting LL, Ko JY, Hsu MM, Sheen TS, Lou PJ, et al. Induction chemotherapy with mitomycin, epirubicin, cisplatin, fluorouracil, and leucovorin followed by radiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol 2001;19:4305-13.
42. Cheng SH, Liu TW, Jian JJ, Tsai SY, Hao SP, Huang CH, et al. Concomitant chemotherapy and radiotherapy for locally advanced nasopharyngeal carcinoma. Cancer J Sci Am 1997;3:100-6.
43. Peters LJ, Withers HR. Applying radiobiological principles to combined modality treatment of head and neck cancer - the time factor. Int J Radiat Oncol Biol Phys 1997;39:831-6.
44. Milas L, Nakayama T, Hunter N, Jones S, Lin TM, Yamada S, et al. Dynamics of tumor cell clonogen repopulation in a murine sarcoma treated with cyclophosphamide. Radiother Oncol 1994;30:247-53.
45. Bourhis J, Wilson G, Wibault P, Janot F, Bosq J, Armand JP, et al. Rapid tumor cell proliferation after induction chemotherapy in oropharyngeal cancer. Laryngoscope. 1994;104:468-72.
46. Yau TK, Lee AW, Wong DH, Pang ES, Ng WT, Yeung RM, et al. Treatment of stage IV (A-B) nasopharyngeal carcinoma by induction-concurrent chemoradiotherapy and accelerated fractionation: impact of chemotherapy schemes. Int J Radiat Oncol Biol Phys 2006;66:1004-10.
47. Hitt R, López-Pousa A, Martínez-Trufero J, Escrig V, Carles J, Rizo A, et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 2005;23:8636-45. Erratum in: J Clin Oncol 2006;24:1015.
48. Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, et al; EORTC 24971/TAX 323 Study Group. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007;357:1695-704.
49. Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, et al; TAX 324 Study Group. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007;357:1705-15.
50. Calais G, Pointreau Y, Alfonsi M, Sire C, Tuchais C, Tortochaux J, et al. Randomized phase III trial comparing induction chemotherapy using cisplatin (P) fluorouracil (F) with or without docetaxel (T) for organ preservation in hypopharynx and larynx cancer. Preliminary results of GORTEC 2000-01. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006;24(18S):5506.
51. Hitt R, Grau J, Lopez-Pousa A, Berrocal A, García-Giron C, Belon J, et al. Randomized phase II/III clinical trial of induction chemotherapy (ICT) with either cisplatin/5-fluorouracil (PF) or docetaxel/cisplatin/5-fluorouracil (TPF) followed by chemoradiotherapy (CRT) vs. crt alone for patients (pts) with unresectable locally advanced head and neck cancer (LAHNC). ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006;24(18S):5515.
52. Rischin D, Corry J, Smith J, Stewart J, Hughes P, Peters L. Excellent disease control and survival in patients with advanced nasopharyngeal cancer treated with chemoradiation. J Clin Oncol 2002;20:1845-52.
53. Lee N, Xia P, Quivey JM, Sultanem K, Poon I, Akazawa C, et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys 2002;53:12-22.
54. Wolden SL, Chen WC, Pfister DG, Kraus DH, Berry SL, Zelefsky MJ. Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: update of the Memorial Sloan-Kettering experience. Int J Radiat Oncol Biol Phys 2006;64:57-62.
55. Oh JL, Vokes EE, Kies MS, Mittal BB, Witt ME, Weichselbaum RR, et al. Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal cancer. Ann Oncol 2003;14:564-9.
56. Au E, Ang PT. A phase II trial of 5-fluorouracil and cisplatinum in recurrent or metastatic nasopharyngeal carcinoma. Ann Oncol 1994;5:87-9.
57. Tan EH, Khoo KS, Wee J, Fong KW, Lee KS, Lee KM, et al. Phase II trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinoma. Ann Oncol 1999;10:235-7.
58. Foo KF, Tan EH, Leong SS, Wee JT, Tan T, Fong KW, et al. Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type. Ann Oncol 2002;13:150-6.
59. Zhang L, Zhang Y, Huang PY, Xu F, Peng PJ, Guan ZZ. Phase II clinical study of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma after the failure of platinum-based chemotherapy. Cancer Chemother Pharmacol 2008;61:33-8.
60. Leong SS, Wee J, Tay MH, Toh CK, Tan SB, Thng CH, et al. Paclitaxel, carboplatin, and gemcitabine in metastatic nasopharyngeal carcinoma: a Phase II trial using a triplet combination. Cancer 2005;103:569-75.
61. Leong SS, Wee J, Rajan S, Toh CK, Lim WT, Hee SW, et al. Triplet combination of gemcitabine, paclitaxel, and carboplatin followed by maintenance 5-fluorouracil and folinic acid in patients with metastatic nasopharyngeal carcinoma. Cancer 2008 Jul 9 [Epub ahead of print].
62. Hong RL, Sheen TS, Ko JY, Hsu MM, Wang CC, Ting LL. Induction with mitomycin C, doxorubicin, cisplatin and maintenance with weekly 5-fluorouracil, leucovorin for treatment of metastatic nasopharyngeal carcinoma: a phase II study. Br J Cancer 1999;80:1962-7.
63. Toh HC, Tan EH, Thng CH, Yap SP, Lee KM, Phoon YP, et al. Non-myeloablative allogeneic blood stem cell transplantation (NMBSCT) ± donor lymphocyte infusion (DLI) for chemorefractory advanced nasopharyngeal carcinoma (NPC). ASCO Annual Meeting Proceedings. J Clin Oncol 2006;24(18S):2549.
64. Gottschalk S, Bollard C, Straathoff K, Shaffer D, Torrano V, Cooper-Havlik D, et al. Adoptive Immonotherapy for Nasopharyngeal Carcinoma. Proceedings East-West Symposium in Nasopharyngeal Carcinoma. Brisbane, Australia, 2007.
65. Comoli P, Pedrazzoli P, Maccario R, Basso S, Carminati O, Labirio M, et al. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J Clin Oncol 2005;23:8942-9.
66. Seow A, Koh WP, Chia KS, Shi LM, Lee HP, Shanmugaratnam K. Trends in Cancer Incidence in Singapore 1968-2002. Singapore: Singapore Cancer Registry, 2004. Report No 6.